A clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics today announced that it has initiated dosing in a pediatric Phase 1 study evaluating CodaVax™-RSV, a live-attenuated, intranasal vaccine candidate for the prevention of disease caused by the Respiratory Syncytial Virus (RSV).
Read More
